EZH2 and neoplasm: In this study, compared with doxorubicin, dual inhibition of H3K9me2 and H3K27me3 with the G9a inhibitor, UNC0642, and the EZH2 inhibitor, UNC1999, promoted tumor cell senescencewithout triggering SASP (Figure 3).